13 Best Healthcare Dividend Stocks to Invest in

7. Bristol-Myers Squibb Company (NYSE:BMY)

Number of Hedge Fund Holders: 88

An American pharmaceutical company, Bristol-Myers Squibb Company (NYSE:BMY) offers a wide range of related services and products to its consumers. The company is focusing its growth strategy on a pipeline of promising new treatments, with particular emphasis on its neuroscience drug, Cobenfy. If clinical trials yield positive results, this medication could significantly impact the company’s financial outlook.

Currently approved for schizophrenia, Cobenfy has the potential to generate up to $2 billion in peak sales from this indication alone. However, its true market opportunity lies in ongoing Phase III trials exploring its use for adjunctive schizophrenia treatment and Alzheimer’s disease psychosis. If the Alzheimer’s trial is successful, peak sales could soar to nearly $10 billion, making it a transformative asset for Bristol-Myers Squibb Company (NYSE:BMY).

In the fourth quarter of 2024, Bristol-Myers Squibb Company (NYSE:BMY) posted revenue of $12.34 billion, reflecting a 7.5% year-over-year increase. The company’s Growth Portfolio was a key driver, with revenue surging 21% to $6.4 billion, driven by strong demand for its leading treatments. Sales of Reblozyl, Breyanzi, and Camzyos saw substantial gains, climbing 71%, 125%, and 101%, respectively.

Bristol-Myers Squibb Company (NYSE:BMY) is a solid dividend payer, having paid regular dividends for the past 93 years. In addition, it maintains 16 consecutive years of dividend growth, which makes it one of the best dividend stocks on our list. Currently, it pays a quarterly dividend of $0.62 per share and has a dividend yield of 4.13%, as of March 20.